Table 4.

Outcomes, instruments used, and effects of decisions aids evaluated in the included one-group pretest-posttest design study

Outcomes	Instruments used for assessment	Pretest-posttest study using the instrument	Score (S.D.)	p-value	Main results
Decision related outcomes
Decisional conflict	Decisional Conflict Scalea	Metcalfe 2007 [27]	Pre-test 36.2 (16.4), Post-test 23.0 (15.2)	0.001	Significantly less decisional conflict after using the DA.
Strenght of treatment preference	15-point scale	Metcalfe 2007 [27]	RR-M:		Significantly fewer women in the DA group were uncertain about RR-M and RR-O.
			Pre-test No 14, Yes 3, Unsure 3
			Post-test No 10, Yes 4, Unsure 6	0.009
			RR-O:
			Pre-test No 5, Yes 12, Unsure 3
			Post-test No 2, Yes 15, Unsure 3	0.003
			Tamoxifen:
			Pre-test No 10, Yes 1, Unsure 9
			Post-test No 11, Yes 5, Unsure 4	0.12
Information related outcomes
Risk perception	BC risk, mutation carriersb	Metcalfe 2007 [27]	Pre-test 65.1 (16.1), Post-test 73.6 (13.4)	0.05	Significantly better risk perception after using the DA.
	BC, risk after RR-M, mutation carriersb	Metcalfe 2007 [27]	Pre-test 71.8 (22.0), Post-test 84.2 (18.2)	0.005	Significantly better risk perception after using the DA.
	BC, risk after RR-O, mutation carriersb	Metcalfe 2007 [27]	Pre-test 43.2 (20.0), Post-test 65.0 (13.3)	0.001	Significantly better risk perception after using the DA.
	BC, risk with Tamoxifen, mutation carriersb	Metcalfe 2007 [27]	Pre-test 50.0 (19.0), Post-test 56.6 (10.0)	0.17	No significant difference.
	BC, risk with mammography, mutation carriersb	Metcalfe 2007 [27]	Pre-test 21.5 (28.0), Post-test 13.5 (22.8)	0.11	No significant difference.
Health outcomes
Distress	Impact of Event Scalea	Metcalfe 2007 [27]	Pre-test 22.7 (13.7), Post-test 19.9 (14.5)	0.24	No significant difference.

DA decision aid, BC breast cancer, RR-M risk-reducing mastectomy, RR-O risk-reducing oophorectomy

^ainstrument was validated in a study

^brisk estimates from 0 to 100%